#United States #Cambridge #Clinical Trials #MetaVia #DA-1726

MetaVia Reports Positive Developments in Q3 2026

MetaVia Inc. has announced significant progress in its clinical developments, specifically targeting liver-related cardiometabolic diseases. In their recent report, they disclosed their financial results for the third quarter ending September 30, 2026, alongside a corporate update that outlines their strategic direction.

Positive Clinical Data

One of the highlights is the interim results from the Phase 1 Part 3B study of DA-1726, a novel compound designed to combat metabolic dysfunction and alcohol-related liver diseases. This data was presented at the Precision Liver Symposium, revealing a, "68.1% placebo-adjusted reduction in liver fat."

CEO Hyung Heon Kim expressed confidence in DA-1726's capabilities, noting that after approximately 16 weeks of treatment, participants displayed a significant reduction in liver fat and weight loss. All subjects with a baseline of steatosis demonstrated promising improvements, which can lead to greater treatment implications for patients suffering from liver-related diseases.

This early success has prompted MetaVia to plan a Phase 2 study set to involve 150 participants, aiming for a launch in the latter half of 2027. The objective is to further assess DA-1726's effectiveness for Metabolic Dysfunction-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD).

Leadership Enhancements

In a move to strengthen clinical leadership, MetaVia appointed Dr. Sarah Browne as Chief Medical Officer. Dr. Browne brings over 20 years of experience in clinical development and regulatory science. Her involvement is expected to guide DA-1726 and another drug candidate, vanoglipel, through their upcoming development phases.

Financial Overview

Despite the positive clinical developments, MetaVia recorded a net loss of $4.6 million for the third quarter, compared to a loss of $3.4 million in the same quarter of the previous year. The increase in the loss was attributed mainly to rising research and development expenses related to DA-1726's ongoing development. Total operating expenses for the quarter amounted to approximately $4.7 million, reflecting heightened investment in R&D efforts.

Expenses Breakdown

Research and Development expenses rose to $2.6 million, an increase from $1.9 million year-over-year. This uptick was largely driven by higher direct costs linked to DA-1726's clinical development, although partially balanced by lower indirect consulting fees. General and Administrative (GA) expenses also increased, reaching $2.1 million from $1.6 million in the previous year.

The company's total cash and cash equivalents stood at $8.8 million at the end of September 2026, a reduction from $10.3 million at the end of 2025, signaling the need for MetaVia to manage resources carefully as they progress through various clinical trials.

Looking Forward

In addition to DA-1726, MetaVia is concurrently advancing vanoglipel, a G-protein-coupled receptor 119 (GPR119) agonist, which shows promise for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). A Phase 2a proof-of-concept study is anticipated to commence in early 2027.

In sum, despite the financial setbacks, MetaVia's strategic plan combined with their clinical advancements emphasizes a strong and focused approach to tackling liver disease. The coming months hold significant potential for further breakthroughs as they strive to meet the pressing medical needs in this area.